Potassium-competitive acid blockers: Clinical pearls and practical insights.

Potassium-competitive acid blockers (P-CABs) are a new class of acid-suppressing drugs; to date, only one of them (vonoprazan) has been approved for use in the United States. The authors of this article review how P-CABs (and vonoprazan in particular) differ from proton pump inhibitors (PPIs), evidence supporting their effectiveness, indications for vonoprazan, and ongoing and future studies.